MG
INDV icon

Marex Group’s Indivior Pharmaceuticals INDV Stock Holding History

Marex Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,413
Closed -$409K – 1239
2026
Q1 		$409K Buy
+13,413
New +$443K ﹤0.01% 678

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marex Group's INDV Position: Q2 2026 in Review

Marex Group sold out of Indivior Pharmaceuticals (INDV) in Q2 2026, closing a stake of 13,413 shares — an estimated $409K sold.

Marex Group first reported a position in INDV in Q1 2026 and held it in 1 quarter. The position peaked at $409K in Q1 2026. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Marex Group reported no remaining Indivior Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Marex Group sold 13,413 Indivior Pharmaceuticals shares in Q2 2026, an estimated $409K.
  • Marex Group first reported a position in Indivior Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Marex Group's Indivior Pharmaceuticals position peaked at $409K in Q1 2026.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.